KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2026)

Aquestive Therapeutics has reported Current Deferred Revenue over the past 9 years, most recently at $20.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 1854.39% year-over-year to $20.5 million; the TTM value through Dec 2025 reached $20.5 million, up 1854.39%, while the annual FY2025 figure was $20.5 million, 1854.39% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $20.5 million at Aquestive Therapeutics, up from $1.1 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $37.1 million in Q2 2023 and troughed at $642000.0 in Q2 2021.
  • A 5-year average of $13.2 million and a median of $6.6 million in 2021 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 2220.95% in 2023 and later tumbled 97.04% in 2024.
  • Year by year, Current Deferred Revenue stood at $765000.0 in 2021, then soared by 97.78% to $1.5 million in 2022, then surged by 2140.32% to $33.9 million in 2023, then plummeted by 96.91% to $1.0 million in 2024, then surged by 1854.39% to $20.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for AQST at $20.5 million in Q4 2025, $1.1 million in Q3 2025, and $21.0 million in Q2 2025.